25-gauge PPV: safe and effective

Article

25-gauge pars plana vitrectomy (PPV) appears to be safe and effective for the treatment of epiretinal membranes.

25-gauge pars plana vitrectomy (PPV) appears to be safe and effective for the treatment of epiretinal membranes, according to a report published online ahead of print by Der Ophthalmologe.

Albrecht Lommatzsch and colleagues from St. Franziskus Hospital MÜnster, Germany investigated 625 eyes from 620 patients who were operated on using the 25-gauge technique between 2002 and 2006.

The epiretinal membranes were successfully removed in all patients and 329 eyes were analyzed with long-term follow-up over 3.1 years. The mean improvement in visual acuity (VA) before and after surgery was -09.41 in logMAR and normal intraocular pressure (IOP) was observed in all patients one week postoperatively. In nine patients with postoperative hypotony and choroidal detachment, an additional suture was required and seven patients developed a retinal detachment. No patients developed endophthalmitis during the follow-up period.

The 25-gauge PPV technique, according to the researchers, appears to be both safe and effective.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.